CUP Stock Overview
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Chugai Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥28.60 |
| 52 Week High | JP¥39.80 |
| 52 Week Low | JP¥22.80 |
| Beta | 0.48 |
| 1 Month Change | -19.66% |
| 3 Month Change | -13.33% |
| 1 Year Change | 25.44% |
| 3 Year Change | -6.75% |
| 5 Year Change | 54.29% |
| Change since IPO | 533.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| CUP | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -5.5% | 2.3% | 0.5% |
| 1Y | 25.4% | -28.6% | 1.3% |
Return vs Industry: CUP exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: CUP exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| CUP volatility | |
|---|---|
| CUP Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CUP's share price has been volatile over the past 3 months.
Volatility Over Time: CUP's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1925 | 7,604 | Osamu Okuda | www.chugai-pharm.co.jp |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases.
Chugai Pharmaceutical Co., Ltd. Fundamentals Summary
| CUP fundamental statistics | |
|---|---|
| Market cap | €47.90b |
| Earnings (TTM) | €1.95b |
| Revenue (TTM) | €6.21b |
24.5x
P/E Ratio7.7x
P/S RatioIs CUP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CUP income statement (TTM) | |
|---|---|
| Revenue | JP¥1.04t |
| Cost of Revenue | JP¥334.93b |
| Gross Profit | JP¥701.15b |
| Other Expenses | JP¥374.78b |
| Earnings | JP¥326.37b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 25, 2024
| Earnings per share (EPS) | 198.37 |
| Gross Margin | 67.67% |
| Net Profit Margin | 31.50% |
| Debt/Equity Ratio | 0% |
How did CUP perform over the long term?
See historical performance and comparisonDividends
1.7%
Current Dividend Yield40%
Payout RatioDoes CUP pay a reliable dividends?
See CUP dividend history and benchmarks| Chugai Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Jun 27 2024 |
| Dividend Pay Date | Aug 30 2024 |
| Days until Ex dividend | 62 days |
| Days until Dividend pay date | 126 days |
Does CUP pay a reliable dividends?
See CUP dividend history and benchmarks